Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Hepatitis E confirmed in Gulu
Gulu Hepatitis E has been confirmed in Odeke Sub-county in Gulu District. The District Health Educator Mr Okot Lukaki said three cases have been reported. He said a task force has been created to ensure cleanliness especially in the camps. Mr Lukaki said

New hepatitis C virus vaccines study findings reported from Research Center for Infectious Diseases
- (NewsRx.com) -- Fresh data on hepatitis C virus are presented in the report 'Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C.' According to recent research published in the journal

Hepatitis E Risk 'On the Rise'
(UN Integrated Regional Information Networks/All Africa Global Media via COMTEX News Network) -- More people are at risk of contracting the Hepatitis E virus (HEV) in the northern Uganda district of Kitgum, according to a surveillance health report. 'The

UPDATES AND COMMENTARY RSS Feed

Good News for Non-Responders to HCV Combination Therapy
A Phase 3 trial evaluating ZADAXIN® (thymalfasin) as a potential third component for Hepatitis C traditional combination therapy has just been completed. Although the data is currently being analyzed and won't be available until later in the year, the lead...

Purer, Less Costly Interferon for Hepatitis C and B Treatment
The Taiwan-based biopharmaceutical company PharmaEssentia Corp. is testing P1101, its third-generation PEG-interferon-alpha drug candidate. Because it is a longer-lasting, purer interferon that is less costly to produce, P1101 could enhance the treatment options for Hepatitis C and B....

New Technology May Help Treat Hepatitis
While pharmaceutical companies are racing to find safer, more effective treatments for viral Hepatitis C and B, physicists from Arizona have a unique perspective on accomplishing the same goal. Learn how these scientists believe the virus could be rendered harmelss...

J Hepatol 1997 Jun;26(6):1173-1178

HCV genotypes in patients with liver disease of different stages and severity.

Mangia A, Cascavilla I, Lezzi G, Spirito F, Maertens G, Parlatore L, Saracco G, Rizzetto M, Andriulli A

Division of Gastroenterology, Hospital Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy.

AIMS/MATERIAL:

Hepatitis C virus (HCV) genotyping was performed in 213 anti-HCV-positive patients with chronic liver disease ranging from minimal histological changes to hepatocellular carcinoma. One hundred and twenty-two patients had non-cirrhotic chronic active or persistent hepatitis (including 29 who were asymptomatic with persistently normal ALT levels) (chronic liver disease group). The other 91 had hepatocellular carcinoma and, in all but three cases, cirrhosis (hepatocellular carcinoma group).

RESULTS:

The overall prevalence of HCV variants was: 54.9% type 1b, 37.8% type 2, 2.5% type 1a, 2.0% type 3a, 2.0% type 4a. The genotype distribution showed no relation to the stage (chronic liver disease vs. hepatocellular carcinoma) or severity (chronic active vs. chronic persistent hepatitis) of the liver disease, or to the duration of the disease (less than 10 years vs. >10 years). Within the hepatocellular carcinoma group, the duration of type-1b disease was similar to that of type-2 infections. Ages at the time of infection and genotype were both independently associated with progression to cirrhosis and hepatocellular carcinoma, but multivariate analysis revealed that the effect of age was much stronger than that of genotype 1b.

CONCLUSIONS:

The predominance of HCV type 1b in this study reflects the higher frequency of this variant in our area. Our findings indicate that infections caused by each HCV genotype are capable of progressing to hepatocellular carcinoma.

PMID: 9210601, UI: 97354307

table Of Contents

Hepatitis Central™

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 04 Jul 2008